Headquarters USAF Human Systems Division
Brooks Air Force Base, TX 78235.
Aviat Space Environ Med 1991
May;62(5):432-5
ABSTRACT
Modafinil, a novel stimulant which has several remarkable features that
distinguish it from other stimulants, has been developed by Lafon, a French
pharmaceutical company. Unlike the amphetamines, for example, modafinil is
reported to have minimal peripheral side effects at therapeutic doses. It also
appears to have a low abuse potential, does not interfere with normal sleep,
and does not seem to produce tolerance. It improves vigilance especially in
sleep-deprived subjects. It has been used clinically for up to 3 years in the
treatment of narcolepsy and idiopathic hypersomnia. It could be an ideal
replacement for amphetamine in short-term operations in which fatigue might
threaten the successful completion of a mission. We recommend that military
laboratories experienced in studying sustained performance include modafinil
or perhaps a more selective alpha 1 receptor agonist in their investigations.
BACK to
order
1. Modafinil for
sustaining the alertness of helicopter pilots
2. Modafinil augmentation
of antidepressant treatment
3. Modafinil the
unique properties of a new stimulant
4. Modafinil children
with attention-deficit/hyperactivity disorder
5. Modafinil tolerability
in healthy male volunteers
6. Modafinil successful
treatment of hypersomnia & narcolepsy
7. Modafinil narcolepsy:
symptoms and management
8. Modafinil
amplification of cortical serotonin release
9. Modafinil
treatment of alcoholic organic brain syndrome
10. Modafinil
effect on melatonin, cortisol, and growth hormone
11. Modafinil
in obstructive sleep apnea-hypopnea syndrome